Oculis Holding AG Ordinary shares

Oculis trades with a remarkably depressed RSI of 32.2, deep in oversold territory, yet carries minimal short interest at just 0.96% of float—suggesting the weakness isn't driven by bearish positioning but rather fundamental concern or broader market indifference. The company's lack of a P/E ratio indicates unprofitability, which paired with an $1.8B market cap on a clinical-stage ophthalmology player, points to valuation buoyed by speculative potential rather than earnings power. The oversold technical reading combined with negligible short covering demand creates an asymmetric risk setup where a positive catalyst could trigger sharp upside, but current momentum offers few near-term conviction signals for a turnaround without news catalysts.